Robert Nesse, MD, the senior director of Policy and Payment Reform at Mayo Clinic, discussed the impact of healthcare consolidation for consumers, whether or not they are aware of it, and how the government will respond to this consolidation.
Robert Nesse, MD, the senior director of Policy and Payment Reform at Mayo Clinic, discussed the impact of healthcare consolidation for consumers, whether or not they are aware of it, and how the government will respond to this consolidation.
Transcript (modified)
What are consumer reactions to consolidation in healthcare? Do they know it’s happening? Do they know why it’s happening?
I don’t belive they’re thinking about the megastructures of what’s going on in healthcare, but it can impact them very immediately, and that would be if their provider has changed, their employment status or somebody else’s has changed, the insurance model can change, and then that patient can no longer go to that provider or, at least, not until they change their insurance. Then it’s immediate. And the patient can’t put that into some larger context so that hits immediately.
Another thing I think can happen is as these models change very quickly, benefits models change, too. People that are used to one set of benefits can end up in trouble unless they read carefully the fine print, if you will, of the insurance model going forward—even the bold print of the insurance model going forward—in order to make the transition.
In 2015 there were a number of large healthcare mergers announced. Do you think we’ll start to see the government cracking down on these mergers?
It depends on how they turn out. So remember that while we might have all heard about 50 insurance company mergers, 500 medical groups merged and were acquired last year, in 2015. This is being done not just for market power, there are forces that really the government would like in terms of coordinated care, population health models, more advanced analytics, meaningful use of electronic medical records—all of those require groups to get bigger.
So you really can’t say we want a model in which people require or need integrated care to be successful both in the provider viewpoint and a patient viewpoint, and then say we can’t support the structure that allows that. So I don’t think they’ll be stopped, I think they’ll be heavily regulated and that’s probably appropriate.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More